Form 4: Evoke Pharma Director, Vickie S. Reed, Acquires Stock Options
SEC Form 4 Filing
Director Vickie S. Reed acquired stock options for 1,250 shares of Evoke Pharma Inc. common stock on May 21, 2025.
Summary
- Vickie S. Reed, a director of Evoke Pharma Inc., filed a Form 4 to report a transaction.
- On May 21, 2025, Reed acquired stock options for 1,250 shares of common stock at an exercise price of $3.453.
- The options vest on the one-year anniversary of the grant date, contingent upon continued service to the issuer.
- Following the reported transaction, Reed directly owns 8,333 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.
Key Dates
| Date | Description |
|---|---|
| 05/21/2025 | Date of the stock option transaction. |
| 05/20/2035 | Expiration date of the stock options. |
Keywords
Evoke Pharma, Stock Options, Form 4, Director, Beneficial Ownership, EVOK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.